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Muscle regeneration declines with aging andmyopa-
thies, and reprogramming of differentiated muscle
cells to their progenitors can serve as a robust
source of therapeutic cells. Here, we used the Cre-
Lox method to specifically label postmitotic primary
multinucleated myotubes and then utilized small
molecule inhibitors of tyrosine phosphatases and
apoptosis to dedifferentiate these myotubes into
proliferating myogenic cells, without gene overex-
pression. The reprogrammed, fusion competent,
muscle precursor cells contributed to muscle regen-
eration in vitro and in vivo and were unequivocally
distinguished from reactivated reserve cells because
of the lineage marking method. The small molecule
inhibitors downregulated cell cycle inhibitors and
chromatin remodeling factors known to promote
and maintain the cell fate of myotubes, facilitating
cell fate reversal. Our findings enhance under-
standing of cell-fate determination and create novel
therapeutic approaches for improved muscle repair.
INTRODUCTION
Skeletal muscle represents a classic example of terminal differ-
entiation wherein myogenic proliferating cells expressing Pax7
andMyoD permanently withdraw from the cell cycle upon serum
deprivation and physiologically fuse into multinucleated myo-
tubes expressing muscle differentiation markers myogenin and
eMyHC (Okazaki and Holtzer, 1966; Olson, 1992; Rudnicki and
Jaenisch, 1995). The regenerative capacity of muscle stem cells
declines upon aging and in certain diseases, exemplified by
Duchennemuscular dystrophy. Hence, studying reprogramming
of terminally differentiated muscle cells to their proliferating
progenitors holds not only theoretical value but is also therapeu-
tically relevant. The reprogramming from myotubes to myogenic
precursor cells is particularly challenging because myogenic
proliferating cells not only undergo postmitotic arrest, but also
physically fuse with each other to formmultinucleated myotubes
during their terminal differentiation. Once these cells terminally
differentiate, they are incapable of reentering into mitosis even
when switched to serum-rich medium (Endo and Nadal-Ginard,
1986, 1998; Stockdale and Holtzer, 1961). In contrast, reserveChemistry & Biology 18, 1153–116cells (myoblasts, which remain mononucleated upon serum
withdrawal) can reenter cell cycle when switched back to the
mitogen-high serum-rich growth medium (Carnac et al., 2000;
Friday and Pavlath, 2001; Yoshida et al., 1998). Several
advances have been previously made in the field of muscle
dedifferentiation. Overexpression of cyclin D1 and CDK4/6 or
knocking down cell-cycle inhibitors alone or in combination is
insufficient for myotubes to enter mitosis (Latella et al., 2001;
Tiainen et al., 1996). Studies in C2C12 cells have shown that
a fraction of myotubes derived from this cell line can dedifferen-
tiate in the presence of newt extract, myoseverin, or when msx1
or twist are overexpressed (Duckmanton et al., 2005; Hjiantoniou
et al., 2008; McGann et al., 2001; Odelberg et al., 2000; Rosania
et al., 2000). However, the rare dedifferentiated cells were not
tested for their ability to contribute tomuscle regeneration in vivo.
Earlier work has also reported that C2C12 myotubes responsive
to thrombin-activated serum response factor triggers expression
of immediate early genes but is not sufficient for S phase entry
(Lo¨o¨f et al., 2007). Interestingly, the same group also demon-
strated that H3K9 di-methylation remains unperturbed in
C2C12 myotubes in the presence of serum, as opposed to sala-
mander myotubes, which readily enter cell proliferation. A recent
study has shown deletion in Ink4a locus in C2C12 immortalized
cell lines, which provides an advantage to C2C12 cells to enter
the cell cycle upon knockdown of Rb. Knockdown of pRb in
conjunction with Arf can induce cell-cycle entry in primary myo-
cytes but not in primary myotubes, where nuclei get arrested at
the onset of mitosis (Pajcini et al., 2010). Nevertheless, the
process of dedifferentiation of primary multinucleated myotubes
is still not well understood, and most of the previous studies
relied on the overexpression of exogenous genes. Some of the
previous studies have employed single myocyte and myotube
isolation, which can lead to preferential selection of those myo-
tubes that survive such process and does not clear ambiguity
of reserve cells that can come along with myotubes. Sparse
plating of myoblasts was also tried, but that prevents formation
of multinucleated myotubes and limits the study to myocytes.
To address these challenges, we performed muscle reprogram-
ming studies in differentiated lineage-marked primary myotubes
generated by the physiological fusion of Rosa26-Lox-YFP
myoblasts with Cre-expressing myoblasts, where the multinu-
cleated myotube cell fate results in the recombination of YFP
locus and expression of YFP. Our work critically examined and
identified small molecule inhibitors that are necessary and suffi-
cient for the dedifferentiation of myotubes to their progenitor
cells without forced expression of specific genes. Briefly, these6, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1153
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Figure 1. LineageMarking of Primary Myotubes by
Cre-Lox Method
(A) Schematic of the system. Wild-type myoblasts (MB)
derived fromC57BL/6mice were infectedwith Ad-Cre and
subsequently cocultured with Lox-YFP MB obtained from
Rosa 26-YFP reporter mice in differentiation medium (DM)
to form myotubes. The fusion of these two populations of
MB led to the excision of stuffer sequence (green circle) by
Cre recombinase activity to give rise to lineage marked
YFP-expressing myotubes (green). Self fusion among the
two populations of MB will give rise to YFP-negative
myotubes (colorless). These lineage marked myotubes
were then used in dedifferentiation studies.
(B) Fusion-dependent, Cre-Lox mediated labeling of
myotubes upon coculture of Ad-Cre MBwith Lox-YFP MB
in DM. As described in (A), wild-type MB were cocultured
with Lox-YFP MB (1:2 ratio) in DM to induce formation of
myotubes. Endogenous YFP fluorescence in myotubes
was observed by 72–96 hr, as shown by epifluorescent
images. In control infection with control Ad-RFP virus, no
YFP fluorescence was observed. No YFP expression was
observed upon coculture of Ad-Cre MB and Lox YFP MB
in GM where myoblasts did not undergo physiological
fusion to form myotubes.
(C) Western blotting to determine YFP expression using
lysates from Lox-YFP MB, Ad-Cre MB cocultured with
Lox-YFP MB in GM and parallel in DM. YFP protein was
observed in the myotubes, which arose from fusion of
Ad-Cre and Lox-YFP MB in DM.
(D) qRT-PCR analysis for YFP gene expression. RNA was
extracted from Ad-Cre, and Lox-YFP MB was cocultured
in GM and in DM for 96 hr to detect the levels of YFP and
Cre recombinase by qRT-PCR. Data were normalized to
internal control GAPDH. Error bars indicate mean and
standard deviation, n = 3. YFP mRNA levels was only
observed in Ad-Cre-Lox-YFP+ myotubes while Cre re-
combinase expressed in both the cocultures of Ad-Cre
and Lox-YFP MB in GM and in DM. The fusion-dependent
marking of myotubes was clearly and robustly mediated
by this adaptation of the Cre-Lox method, and no mono-
nucleated cells expressed YFP.
See also Figure S1.
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Myotube Reprogramming by Small Molecule Inhibitorsstudies demonstrate that, in the presence of tyrosine phospha-
tase (BpV) and apoptosis (Q-VD) inhibitors, Cre-Lox lineage-
marked myotubes exhibited altered morphology, down-regu-
lated terminal differentiation markers, up-regulated markers of
myogenic progenitor cells, and attenuated the cell-cycle inhibi-
tors p21, p15, and p16. According to BrdU incorporation, the
dedifferentiation efficiency was 12%. To further validate the
labeling technique and dedifferentiation of labeled myotubes,
the lineage-markedmyotubes, followed by their dedifferentiation
into mononucleated cells, were captured by time lapse micro-
scopy. The dedifferentiated proliferating cells maintained their
myogenic identity and were capable of expansion in culture, as
well as redifferentiation intomyotubes in vitro and in vivo. Further-
more, at the level of molecular mechanism, this work established1154 Chemistry & Biology 18, 1153–1166, September 23, 2011 ª2011 Elsevier Ltd Allthat phosphatase and apoptosis inhibitors
caused down-regulation of a number of chro-
matin remodeling factors and components that
are necessary for the maintenance of terminal
myogenic differentiation, thus predisposingmyotubes for muscle precursor cell fate. The controlled re-
programming from postmitotic multinucleated terminally differ-
entiated cell fate into a progenitor cell fate of the same lineage
provides new insights into adult tissue formation and enables
unique clinical strategies for enhancing muscle regeneration.
RESULTS
Fusion-Dependent Lineage Marking of Primary
Myotubes
To overcome instances of mistaken cell identity during reprog-
ramming studies, we first established a method to genetically
and irreversibly label terminally differentiated myotubes using
the Cre-Lox technique (Figure 1A). The Cre-Lox system hasrights reserved
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Figure 2. Immunodetection of YFP and
Muscle Specific Markers
(A–D) YFP+ myotubes obtained after Cre-Lox
fusion express muscle differentiation marker and
does not incorporate BrdU. Cre-Lox YFP+ my-
otubes cultures were coimmunostained with
muscle differentiation markers eMyHC (A), my-
ogenin (B), p21 (C), and DNA synthesis label BrdU
(D) along with anti-YFP antibody. Representative
images are shown.
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Myotube Reprogramming by Small Molecule Inhibitorsbeen widely used for tissue-specific disruption of genes, utilizing
the P1 bacteriophage Cre recombinase, which specifically
recognizes Lox sites and excises any DNA sequence flanked
by these sites (Nagy, 2000). The schematic of the system is rep-
resented in Figure 1A. Cre recombinase was expressed exoge-
nously by adenoviral mediated infection (Ad-Cre) in wild-type
primary myoblasts (MB). Ad-Cre-infected myoblasts (Cre-MB)
were cocultured with Lox-YFP myoblasts (Lox-YFP MB) derived
from Rosa26 YFP reporter mice (Srinivas et al., 2001) in the ratio
of 1:2, so that more numbers of Lox YFP myonuclei coexist with
Ad-Cremyonuclei in single myotube and yield high expression of
YFP. In standard low-mitogen differentiation-promoting medium
(DMEM, 2% horse serum), these cocultured MB within 72–96 hr
physiologically fused into YFP-expressing myotubes (hence-
forth, YFP+ myotubes), where both Cre and Lox-YFP myonuclei
coexisted (Figure 1B). No mononucleated cells expressing YFP
were observed, thus confirming the validity of this lineage
marking strategy. Adenoviral infection control was also per-
formed by coculturing Ad-RFP infected MB with Lox-YFP MB
in differentiation medium (DM) and this did not yield YFP+ myo-
tubes (Figure 1B).The YFP+ myotubes accounted for around
70% of total myotubes formed within 96 hr. Of these, aroundChemistry & Biology 18, 1153–1166, September 23, 2011 ª60% of YFP+ myotubes had 2–4 myonu-
clei, whereas 30% had 5–7 myonuclei
with an average number of 4.5 myonuclei
per YFP+ myotube. Non-YFP myotubes
that arose from syngeneic fusion events
of Cre-MB or Lox-YFP MB were also
detected. This labeling strategy was
captured by time lapse microscopy en-
compassing a total of 4 days from the
coculture of Cre and Lox YFP myoblasts
to their fusion into multinucleated myo-
tubes (see Movie S1 available online).
Representative images of time lapse
microscopy are shown in Figure S1. To
further rule out any possibility of YFP
expression without physiological myo-
blast fusion, specific control experiments
were conducted. The Cre–MB were
cocultured with Lox-YFPMB in mitogenic
growth medium (GM; Ham’s F10, 20%
BGS, 9 ng/ml bFGF-2), where cells re-
mained mononucleated and did not fuse
into myotubes (Figure 1B). After 96 hr of
coculture in GM, cells were processed
for Western blotting (Figure 1C), qRT-PCR analysis (Figure 1D), and immunostaining (Figure S1) for
YFP expression. No YFP expression was observed by any of
these techniques. A more stringent control experiment was
performed to check the possibility of horizontal transfer of Cre
recombinase, without complete fusion process. For this, Cre
myoblasts were cultured in differentiation medium to form myo-
tubes. Later, Lox YFPMB (23 105 cells) were added to 96-hr-old
Cre-expressing myotubes, and cultures were switched to mito-
genic growth medium for 72–96 hr. As seen in Figure S1E,
both epifluorescent imaging and anti-YFP staining confirmed
the absence of YFP-expressing mononucleated cells without
physiological fusion of Cre-MB and Lox-YFP MB into myotubes.
These results clearly show that indeed YFP+ myotubes arose
only from the fusion of Cre and Lox-YFP MB in DM. The results
obtained and quantified with YFP live-direct fluorescence were
completely consistent with the data produced using anti-YFP
immunofluorescence, and both assays were routinely employed
throughout these studies. The YFP+ myotubes were positive for
muscle differentiation markers myogenin and eMyHC and for
CDK inhibitor p21 (which indicates the postmitotic state) (Figures
2A–2C). Furthermore, these YFP+ myotubes did not incorporate
BrdU, confirming that all YFP+ marked cells produced by fusion2011 Elsevier Ltd All rights reserved 1155
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Figure 3. BpV with Q-VD Dedifferentiates the Irreversibly Labeled YFP+ Myotubes to YFP+ Proliferating Mononucleated Cells
(A) Myotube dedifferentiation strategy. MB infected with Ad-Cre were cocultured with Lox-YFP MB in DM for 4 days to give rise to YFP+ myotubes. These were
treated with 10 mMBpV plus 10 mMQ-VD in parallel with other experimental conditions for two days in DM. The treatedmyotubes were then switched tomyoblast
GM, which was replaced fresh every day. YFP+ mononucleated cells were observed around day 10.
(B) Dedifferentiation of YFP+ myotubes to YFP+ proliferative cells. YFP+ myotubes cultures were treated with the BpV plus Q-VD and were photographed every
day. The addition of BpV plus Q-VD led to morphological changes and when switched to GM these cells expanded as YFP+ mononucleated cells in 72 hr (white
arrow shows YFP+ mononucleated cells). Representative high magnification images of dedifferentiation experiment over the course of 10 days with live Hoechst
is shown by epifluorescent microscopy.
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Myotube Reprogramming by Small Molecule Inhibitorsof Cre and Lox-YFPMB have exited cell cycle and are in postmi-
totic arrest by 96 hr in DM (Figure 2D). These findings establish
an unambiguous lineage marking of terminally differentiated
myotubes that is dependent on physiological myoblast fusion.
Combination of a Tyrosine Phosphatase Inhibitor
and Apoptosis Inhibitor Reprograms Lineage Marked
Myotubes into Proliferating YFP+ Mononucleated Cells
Myotube formation involves many events, such as changes in
cytoskeletal assembly, sequential expression of differentiation-
specific genes, modulation of signaling pathways, and up-regu-
lation of tyrosine phosphatases (Bennett and Tonks, 1997;
Delgado et al., 2003; Lassar et al., 1994; Weintraub, 1993).
Hence, we reasoned that global transient inactivation of tyrosine
phosphatases would reset signaling in myotubes, making them
receptive to mitogens present in growth medium conditions
and propelling them into cell cycle as well as toward a less-differ-
entiated state. Earlier BpV (a tyrosine phosphatase inhibitor) was
reported to delay differentiation of dividing C2C12 intomyotubes
(Castaldi et al., 2007), and other studies also indicated that
a small percentage of myotubes that enter S-phase upon over-
expression of genes fail to proliferate and succumb to apoptosis
(Endo and Nadal-Ginard, 1998; Latella et al., 2000). Therefore,
we reasoned that if BpV was able to trigger the process of myo-
tube dedifferentiation and that the addition of an apoptosis inhib-
itor (Q-VD) in our studies may help in survival of those myotubes
that might undergo massive restructuring of cell cytoskeleton
simultaneously with the breakage of postmitotic arrest. Using
our lineage marking technique for myotubes, we then explored
whether BpV plus Q-VD (hence forth inhibitor mix) was capable
to reprogram already differentiated primary myotubes to their
muscle progenitor fate. For dedifferentiation assays, inhibitor
mix (10 mM each) was added to YFP+ myotube cultures daily
for two days, after which cultures were switched to GM (Fig-
ure 3A). Remarkably, in the presence of inhibitor mix, a consider-
able number of YFP+ myotubes showed altered morphology and
cleaved into small cells, which were followed by the appearance
of YFP+ mononucleated progeny of the dedifferentiated myo-
tubes (Figure 3B). When myotubes produced by the fusion of
primary myoblasts were treated with BpV alone, cell death
occurred as described in previous studies (Rumora et al.,
2003). Interestingly, in the presence of BpV alone, myotubes
did show apoptosis and few of them gave rise to YFP+ mononu-
cleated cells, albeit at very low frequency (1.18%) in compar-
ison to inhibitor mix treatment, which augmented the dedifferen-
tiation frequency to12%–13% (Figures S2A, S2C, and S2D)
These results demonstrate that the inhibition of apoptosis is
a critical requirement for the dedifferentiation of multinucleated(C) No-treatment (UT). Untreated YFP+ myotubes were grown in similar condition
inhibitor mix is necessary and sufficient for dedifferentiation of genetically labele
(D) Reprogrammed YFP+ mononucleated cells rapidly divide. Cre-Lox-YFP+ myo
for 24 hr and costained with anti YFP and BrdU antibodies. Arrows indicate repr
myotubes do not show any YFP+ mononucleated cells, though BrdU incorpora
images.
(E) Quantification of percentage of BrdU+ YFP+ mononucleated cells out of total n
p < 0.05). Note that many reserve myoblasts reentered cell cycle and incorpora
cultures); these cells, however, were reliably distinguished in our experiments by
See also Figures S2–S5.
Chemistry & Biology 18, 1153–116primary myotubes. In control experiments, no YFP+ mononucle-
ated cells were observed in untreated YFP+ myotubes that were
switched to GM for 72 hr (Figure 3C), or in the presence of Q-VD
alone (Figure S2B). Furthermore, the YFP+ cells derived from the
postmitotic multinucleated myotubes engaged in proliferation,
where 12%–13% of total lineage-marked population was
found to incorporate BrdU during a 24-hr BrdU labeling interval
(Figures 3D and 3E). The former myotube identity of these
YFP+ cells clearly discriminated them from the reactivation of
reserve YFP– myoblasts, which also proliferated and expanded
when myotube cultures were switched to the highly mitogenic
GM (Figure 3D). To rule out any spurious YFP expression in the
absence of Cre-expressing cells and in the presence of inhibitor
mix, 4-day-old Lox YFP myotube cultures were treated with the
inhibitor mix and then switched to growth medium. No YFP
expression was ever observed in these cultures. This clearly
establishes that Lox YFP cells do not spontaneously express
YFP upon addition of inhibitor mix in the absence of Cre recom-
binase (Figure S4A). To capture reprogramming of lineage-
marked myotubes, we also performed time lapse microscopy,
where Ad-Cre-Lox YFP myotubes were labeled for 96 hr, fol-
lowed by the addition of inhibitor mix for another 48 hr, and the
cultures were then switched to GM. Live cell imaging was per-
formed for the total period of 4 days, where inhibitor mix-treated
YFP+ multinucleated myotubes gave rise to YFP+ mononucle-
ated cells (Movie S2). Representative images of the time lapse
imaging can be seen in Figure S3. A combination of a small mole-
cule tyrosine phosphatase inhibitor, BpV, and an apoptosis
inhibitor, Q-VD, was necessary and sufficient for such reprog-
ramming of terminally differentiated muscle cells. Because
inhibition of tyrosine phosphatases induces apoptosis, the
possibility that some aspect of apoptosis may mediate the re-
programming of multinucleated myotubes to undergo dediffer-
entiation was also examined. Doxorubicin (0.2 mM), a classic
inducer of apoptosis that has been studied in muscle (Latella
et al., 2004), was added to Cre-Lox myotube cultures for 48 hr
either alone or in combination with the apoptosis inhibitor. This
was followed by removal of drugs and switching cultures to
growth media conditions for 72–96 hr. We observed reduced
apoptosis by doxorubicin in the presence of apoptosis inhibitor,
but no YFP+ mononucleated cells were observed in these
cultures, in spite of altered morphology of myotubes (Figures
S4B and S4C). This suggests that apoptosis does not mediate
the dedifferentiation of myotubes.
In parallel to these experiments, we also addressed a possible
role of Oct4 in myotube reprogramming, considering the pivotal
reprogramming activity of Oct4 and the ability of this transcrip-
tional factor alone to reprogram neural stem cells (Kim et al.,s and did not show any dedifferentiation events. These data demonstrate that
d myotubes into expanding mononucleated cells.
tubes reprogrammed as depicted in Figures 3B and C, were pulsed with BrdU
esentative BrdU+ YFP+ cells in treated conditions. Untreated cultures of YFP+
tion is seen in non-YFP-cycling mononucleated cells. Inset shows magnified
umber of YFP+ myotubes (shown are the mean and standard deviations, n = 3,
ted BrdU in GM (both in the presence of BpV+ Q-VD and in control untreated
the absence of YFP.
6, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1157
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Myotube Reprogramming by Small Molecule Inhibitors2009). We used our published method (Conboy and Conboy,
2010) to activate endogenous muscle stem (satellite) cells by
injury into hind limb muscle of Tet-Oct4 mice (Hochedlinger
et al., 2005) and derived primary myoblasts that were kept in
DM to form myotubes and then treated or untreated with doxy-
cycline (dox) for 24 and 48 hr, to induce Oct4 protein and
mRNA expression (Figure S5). These Tet-Oct4 myoblasts were
infected with Ad-Cre and were cocultured with Lox-YFP MB in
DM for 96 hr, where myotubes were readily formed (Figure S5).
No significant changes in morphology of myotubes were
observed for up to 48 hr of Oct4 induction, followed by growth
media incubation for an additional 4 days (Figure S5D). In
concert with earlier studies, where it has been reported that
induction of Oct4 in the differentiated cells of the intestine and
hair follicle has no effect on their cellular phenotype (Hochedlin-
ger et al., 2005), our results showed that Oct4 induction up
to 2 days was not sufficient to induce any morphological
changes in myotubes or to promote their dedifferentiation in
GM (Figure S5).
YFP+ Mononucleated Cells from Dedifferentiated
Myotubes Reexpress Markers of Myogenic Progenitors,
Downregulate Markers of Myotubes, Attenuate p21,
and Retain Their Myogenic Potential to Fuse into
De Novo Myotubes
To further assess the properties of reprogrammed cells, mono-
nucleated YFP+ progeny of dedifferentiated myotubes was
FACS-sorted and expanded in culture (Figure S6A). These
YFP+ mononucleated cells were immunostained with antibody
against Ki67 (proliferation marker) and BrdU (S phase marker)
along with YFP. As shown in Figure S6C, these FACS-sorted
expanded YFP+ cells positively immunostained for Ki67 and
incorporated BrdU. Furthermore, cell-cycle analysis by propi-
dium iodide DNA staining confirmed that these cells can prolif-
erate and exist in different phases of cell cycle (Figure S6E). To
confirm that the actively dividing reprogrammed YFP+ cells are
indeed myogenic, they were analyzed for the myogenic markers
Pax7, MyoD1, and differentiation markers myogenin, eMyHC,
and Cdk inhibitor, p21 (Figure 4A). On the basis of the quantifica-
tion of the immunofluorescence, around 70% of YFP+ mononu-
cleated cells expressed high levels of Pax7, and R90%
expressed MyoD1 (Figure 4B). The differentiation capability of
the YFP+ mononucleated cells was tested by switching the
cultures to DM, where normal primary myoblasts exit cell cycle
and fuse into multinucleated myotubes. The YFP+ precursor
cells were found to retain their myogenic potential as they under-
went rapid physiological fusion de novo into myotubes that
expressed typical muscle differentiation markers eMyHC,
myogenin, and p21 (Figure 4C). Thus, the markers of terminal
differentiation that were down-regulated upon myotube reprog-
ramming with inhibitor mix treatment were up-regulated again
when YFP+ myogenic progenitor cells differentiated into de
novo myotubes in the mitogen-low differentiation medium (Fig-
ure 4D). The changes in marker gene expression were also vali-
dated at the transcriptional level by qRT-PCR, which clearly
showed the up-regulation of eMyHC, p21, and myogenin and
down-regulation of Pax7 and MyoD mRNA levels upon differen-
tiation of YFP+ mononucleated cells (Figure 4E). Thus, according
to the profile of myogenic markers and the functional properties,1158 Chemistry & Biology 18, 1153–1166, September 23, 2011 ª201dedifferentiated genetically labeled progeny of primary myo-
tubes acquired the fate of muscle precursor cells or myoblasts.
Reprogrammed YFP+ Cells Can Contribute to In Vivo
Muscle Regeneration
The ultimate test was to make sure that these reprogrammed
cells could contribute to in vivo muscle regeneration under phys-
iological conditions. The dividing dedifferentiated YFP+ cells
were expanded in GM for 1.5–2 weeks and were injected into
cardiotoxin-injured tibialis anterior (TA) of immunodeficient
NOD-SCID mice. Injections of unrecombined Lox-YFP myo-
blasts and buffer medium served as negative controls. Two
weeks after injection, muscles were dissected out, sectioned,
and immunostained for YFP and laminin. YFP+ reprogrammed
cells readily fused with regenerating myofibers and contributed
to muscle repair in vivo (Figure 5). These results establish that
postmitotic myotubes can dedifferentiate into functional,
proliferating myogenic precursor cells that regenerate muscle
tissue after an injury. Importantly, cultured muscle precursor
cells that eagerly regenerate muscle in vivo were produced
from terminally differentiated primary myotubes without an
exogenous gene expression, making this method therapeutically
feasible.
Inhibitor Mix Treatment Modulates Gene Expression
in Myotubes
To address the mechanism by which inhibitor mix facilitated
dedifferentiation of YFP+ myotubes, we analyzed early changes
in expression of eMyHC (a terminal muscle differentiation
marker), myogenin (a muscle marker expressed on onset of
differentiation), and p21, p15, and p16 (CDK inhibitors) in Ad-
Cre-Lox YFP+ myotubes treated with inhibitor mix for 48 hr
(Figures 6A and 6B). By immunofluorescence, over 60% of the
myonuclei in YFP+ myotubes down-regulated myogenin as
compared to untreated myotubes, whereas the levels of p21,
a negative regulator of mitosis that plays an important role in
cell-cycle arrest (Bunz et al., 1998; Cayrol et al., 1998), were
found to be attenuated in approximately 25% of the myonuclei
present in YFP+ myotubes (Figures 6C and 6D). The down-regu-
lation of eMyHC, p21, p15, p16, and myogenin in Ad-Cre-Lox-
YFP+ myotubes treated with inhibitor mix was also confirmed
byWestern blotting experiments and qRT-PCR analysis (Figures
6E and 6F). These results demonstrate that the myogenic cell
fate is reversed at the genetic level in multinucleated myotubes,
before they split into single dividing cells. We also observed that
inhibitor treatment increased the expression of YFP in Cre-Lox
myotubes both at protein and RNA level. As shown earlier in
Figure S4A, Lox YFP myotubes do not express YFP spontane-
ously upon inhibitor mix treatment and in the absence of Cre
recombinase. However, when YFP locus is recombined, the
broad-range phosphatase inhibitor mix, which is known to
modulate numerous signaling pathways by acting at the tran-
scriptional as well as posttranscriptional levels, might activate
ROSA locus at the transcriptional level, thereby increasing YFP
expression.
Studies have also shown that, upon myotube differentiation,
widespread chromatin remodeling occurs, and genes necessary
for differentiation are activated while those for proliferation are
repressed (Forcales and Puri, 2005; Guasconi and Puri, 2009;1 Elsevier Ltd All rights reserved
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Figure 4. Genetically Labeled Progeny of Dedifferentiated Myotubes Have Functional and Genetic Attributes of Muscle Progenitor Cells
(A) Coimmunostaining of FACS-sorted, proliferating YFP+ mononucleated cells for (1) Pax7 and (2) MyoD along with anti-YFP antibody was performed, and
representative images are shown.
(B) Histogram quantifies Pax7- and MyoD-expressing YFP+ mononucleated cells, which represents mean and standard deviation of three independent
experiments.
(C) Dedifferentiated, FACS sorted, YFP+ cells were expanded in GM and cultured in DM for 96 hr where myoblasts typically form myotubes; cultures were
coimmunostained with antibodies specific to YFP and to myotube specific marker (1) eMyHC, (2) myogenin, as well as (3) the CDK inhibitor p21.
(D) Western blotting with antibodies specific for Pax7, MyoD, eMyHC, p21, myogenin, and YFP was performed using protein extracts from Cre-Lox-YFP
myotubes, dedifferentiated YFP+ mononucleated cells, and redifferentiated YFP+ cells as indicated. Actin served as loading control.
(E) Gene expression analysis of muscle differentiation markers. qRT-PCR data in log scale for Pax7, MyoD, myogenin, p21, and eMyHC depicts the relative gene
expression of redifferentiated myotubes to dedifferentiated YFP+ cells. The data represent the mean and standard error for three independent experiments.
See also Figure S6.
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Figure 5. Reprogrammed YFP+ Proliferative Cells Contribute to In Vivo Muscle Regeneration
FACS sorted YFP+ proliferating mononucleated cells were expanded in GM and injected in cardiotoxin injured tibialis anterior (TA) immunocompromised NOD-
SCID mice. Two to three weeks later, TA muscles were dissected out, sectioned at 10 mm, and costained with YFP and laminin to visualize YFP+ myofibers.
Control buffer and Lox YFP myoblast injected TA muscle did not show any YFP+ myofibers.
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Myotube Reprogramming by Small Molecule InhibitorsMcKinsey et al., 2002; Palacios and Puri, 2006; Sartorelli and
Caretti, 2005). Because a subset of labeled myotubes enters
cell cycle and proliferates in GM, we reasoned that inhibitor
mix has a global effect and that perturbation of signaling path-
ways would, in turn, affect chromatin remodeling, thereby facili-
tating reprogramming of myotubes to their progenitor cells. To
analyze these changes during inhibitor mix treatment, PCR
arrays for chromatin enzymes and chromatin remodeling factors
were performed on untreated and inhibitor mix-treated Cre-Lox
YFP myotube cultures (Figure 7). As summarized in Figures 7C
and 7D, Carm1, Suv39h1, and SWI/SNF complex components,
which have been earlier shown to promote myogenic differenti-
ation (Ait-Si-Ali et al., 2004; Chen et al., 2002; de la Serna
et al., 2001), were down-regulated upon inhibitor mix treatment
along with other histone methyltransferases. Tables S1 and S2
provide a complete list of chromatin factor and enzyme genes
modulated by inhibitor mix treatment. These findings suggest
that inhibitor mix down-regulates the chromatin factors and
enzymes dedicated to the maintenance of differentiated state
in primary myotubes, enabling them to respond to the growth
factors present in serum and dedifferentiate to YFP+ proliferating
progenitor cells.
DISCUSSION
Our studies explored the small molecule pharmacological
approach to dedifferentiation and reprogramming that does
not involve overexpression of exogenous genes, which is the
currently searched for method in the field of cell reprogramming.
The use of a broad pharmacological inhibitor of tyrosine phos-
phatases simultaneously with the inhibition of apoptosis was,
in our hands, sufficient to induce actual reprogramming of termi-1160 Chemistry & Biology 18, 1153–1166, September 23, 2011 ª201nally differentiated postmitotic multinucleated skeletal muscle
cells into their progenitors. The use of small molecule inhibitors
for reprogramming studies has high translational significance.
The apoptosis inhibitors used in our studies are a reversible
treatment, have a short half life, and are not present in cells
when expanded in vitro for transplantation experiments. Hence,
the reprogrammed myogenic progenitor cells transplanted with
the aim to alleviate myopathic conditions will not be resistant
to apoptosis and, consequently, will not pose the risk of cancer.
In this work, the irreversible cell-fate lineage marking of myo-
tubeswas based on the fact that terminally differentiated skeletal
muscle cells are normally produced by the fusion of myoblasts.
Thus, Lox-YFP Rosa 26 nuclei and Cre-containing nuclei at
some point coexisted in amultinucleated cell in order to produce
YFP+ myotubes. The Cre-Lox myotube labeling method effi-
ciently distinguishes reserve cells from multinucleated myo-
tubes. Our data show that 4-day-old cultures of YFP+ primary
myotubes express typical muscle differentiation markers, such
as myogenin and eMyHC, express high levels of CDK inhibitor
p21, and do not incorporate BrdU, which strongly suggests
that these YFP-marked cells are indeed terminally differentiated
(Figures 2A–2D). The observation that dividing YFP+mononucle-
ated myogenic progeny were obtained from YFP+ myotubes
unambiguously establishes the reprogramming step toward
a less-differentiated precursor cell. Importantly, such genetic
labeling for the first time demonstrates dedifferentiation of
mature 4-day-old multinucleated primary myotubes into prolifer-
ating fusion-competent myoblasts that expand in vitro and repair
muscle in vivo.
The calculation of reprogramming efficiency from terminally
differentiated myotubes to the muscle progenitor cells is compli-
cated by the fact that heterogenous Cre and Lox YFP myoblasts1 Elsevier Ltd All rights reserved
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Figure 6. Molecular Analysis of Reprogram-
ming in Genetically Labeled Myotubes
Inhibitor mix treatment down-regulates muscle
differentiation marker in Cre Lox-YFP myotubes.
(A and B) Four-day old Ad-Cre-Lox-YFPmyotubes
were untreated/treated with inhibitor mix for 48 hr,
followed by immunodetection of myogenin (A),
p21 (B), and YFP (green), using antibodies specific
for these proteins. Myogenin and p21 were down-
regulated in a subset of YFP+ myotubes (shown by
white arrows). Control myotubes did not change
expression of muscle differentiation markers.
(C and D) The histogram quantifies the percentage
of YFP+/myogenin+, YFP+ myogenin cells and
YFP+/p21+ and YFP+/p21 in the experiment
shown in (A) and (B) (n = 3 ± SD; p*** < 0.001, p** <
0.05).
(E and F) Ad-Cre- Lox-YFP myotubes untreated/
treated with BpV plus Q-VD for 48 hr were
analyzed for protein and mRNA levels. Protein
lysates were subjected to Western blotting for
antibodies against p21, myogenin, and eMyHC.
Actin served as a loading control. q-RT-PCR was
performed on RNA lysates for gene expression
of p21, p15, p16, myogenin, and eMyHC. Data
were normalized to GAPDH and represent mean
and standard deviation of three independent
experiments each done in triplicates (n = 3 ± SD;
p*** < 0.001, p** < 0.05). Untreated sample was
taken as 1.
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Myotube Reprogramming by Small Molecule Inhibitorsform YFP+ myotubes, where varying numbers of both myonuclei
coexist in the same multinucleated myotube. Furthermore, only
Lox YFP myonuclei, and not Ad-Cre MB nuclei, coexisting in
YFP+ myotubes will give rise to YFP+ mononucleated cells
when labeled myotube dedifferentiates. Moreover, the dediffer-
entiation of myotubes that are produced by syngeneic fusion
events was not accounted for in our YFP-labeling method.
Hence, we estimated efficiency by two different methods. By
method 1, the total number of YFP+ mononucleated cells was
divided by the total number of YFP+ myotubes before inhibitor
treatment. According to this method, efficiency was estimatedChemistry & Biology 18, 1153–1166, September 23, 2011 ªas 12%–13% in the presence of inhib-
itor mix as compared to BpV alone, which
was1.18% (Figure S2D). By method 2,
the total number of YFP+ mononucleated
cells was divided by an estimated
number of Lox YFP myonuclei present in
all labeled YFP+ myotubes before inhib-
itor treatment (see Experimental Proce-
dures). This method gave an estimate of
5% in the presence of inhibitor mix
and 0.4% in the presence of BpV alone
(Figure S2D; Experimental Procedures).
For the above reasons, we think that
these calculations give very conservative
estimates of dedifferentiation. No matter
the method of quantification, BpV alone
gave poor reprogramming efficiency and
apoptotic inhibitor was needed to aug-
ment the dedifferentiation likely by facili-tating the survival of those myotubes that undergo reprogram-
ming in the presence of phosphatase inhibitor.
Recent reports have shown that cells expressing higher
levels of antiproliferative genes and those involved in senes-
cence are indeed difficult to reprogram (Li et al., 2009; Utikal
et al., 2009). Because myotubes are postmitotically arrested
cells that express high levels of CDK inhibitors, these may
have low reprogramming efficiency. Studies have indicated
that experimental down-regulation of CDK inhibitors in postmi-
totic myotubes results in accumulation of DNA damage, hinders
cell cycle reentry, and cause DNA fragmentation and apoptosis2011 Elsevier Ltd All rights reserved 1161
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Figure 7. Inhibitor Mix Treatment Modulates Chromatin Remodeling Factors and Enzymes
(A and B) Clustergram analysis of chromatin remodeling factors and enzymes for Ad-Cre-Lox YFPmyotubes treated and untreated with BpV plus Q-VD (inhibitor
mix) for 48 hr using SA Biosciences/QIAGEN PCR arrays; 0.5 mg of RNA isolated from three independent set of experiments of Ad-Cre-Lox YFP myotubes were
reverse transcribed, and gene expression profile was monitored.
(C and D) Histogram representation for few set of genes normalized by Hprt gene levels. Control untreated was taken as 1 (n = 3 ± SD; p*** < 0.001, p** < 0.05).
See also Tables S1 and S2.
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Myotube Reprogramming by Small Molecule Inhibitors(Pajalunga et al., 2010) It has been shown that dividing cells
robustly repair DNA damage (Nouspikel and Hanawalt, 2002),
and because our dedifferentiated cells are cultured in mitogen-
high growth medium (following the BpV and apoptosis inhibitor
treatments) and are actively dividing, any DNA damage accumu-
lated in myotubes is likely to be repaired during the process of
DNA replication. Notably, our results definitively demonstrate
that reprogrammed myotubes give rise to functional muscle
progenitor cells which form new muscle in vitro and in vivo;
hence, no irreversible DNA damage or mutations occurred to
compromise the myogenic properties of the dedifferentiated
cells. Recent studies have also shown that inhibition of Rb and1162 Chemistry & Biology 18, 1153–1166, September 23, 2011 ª201p16/p19 can induce cell-cycle entry in postmitotic myocytes
(Pajcini et al., 2010). Our work conducted on 4-day-old mature
myotubes not only down-regulated CDK inhibitors and muscle
differentiation markers but also decreased gene expression of
chromatin remodelers that maintain differentiated state. The
role of chromatin organization in establishment andmaintenance
of cell fates has beenwell defined. It has also been shown to play
a role in the commitment of myoblast to terminally differentiated
myotubes, because different signaling pathways have been
shown to modulate chromatin signaling in muscle progenitor
cells upon differentiation (Caretti et al., 2004; de la Serna et al.,
2001; McKinsey et al., 2002; Palacios and Puri, 2006; Saccone1 Elsevier Ltd All rights reserved
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Myotube Reprogramming by Small Molecule Inhibitorsand Puri, 2010). Recent work has also demonstrated the stage-
specific role of Ezh2 in muscle regeneration, where Ezh2
occupies the Pax7 regulatory sequences in a differentiated state
(Palacios et al., 2010). This suggests that, in spite of down-regu-
lation of Ezh2 upon differentiation, as reported earlier (Caretti
et al., 2004), a certain level of Ezh2 along with other polycomb
members would be required to maintain muscle progenitor
genes in a repressed state. Our PCR arrays on Cre-Lox myo-
tubes after inhibitor mix treatment demonstrate significant
down-regulation of Ezh2 and other polycomb members, as
compared to untreated myotubes, suggesting the creation of
sensitized background in myotubes that may force them to reex-
press muscle progenitor genes and enter the cell cycle. The
conversion of cell fates due to enhanced cell fate plasticity in pol-
ycomb compromised backgrounds has been documented in
other model systems, such as flies (Lee et al., 2005) and worms
(Yuzyuk et al., 2009). In this regard, our work highlights the fact
that key players in maintaining and establishing a terminally
differentiated state need to be erased transiently at the epige-
netic level in order to switch a differentiated state to a less differ-
entiated state within the same cell lineage.
Because we used a generic tyrosine phosphatase and
apoptosis inhibitor, which is expected to modulate signaling in
many biochemical pathways, the down-regulation of specific
chromatin remodeling factors predisposed primary myotubes
to respond to the mitogens of GM, thereby changing their cell
fate to that of proliferating myogenic precursor cells. Interest-
ingly, although upon the addition of inhibitor mix there were
profound changes in the morphology of many myotubes, only
a subset of these myotubes dedifferentiated into proliferating
mononucleated precursor cells. As there is a temporal progres-
sion toward the degree of terminal differentiation in myotubes,
there might be a specific time window when myotubes would
be more responsive to the treatment and capable of undergoing
cell fate reversal. Future work would determine the exact role of
chromatin remodeling factors in acquiring muscle progenitor cell
fate from the multinucleated postmitotic differentiated state.
Since there is sequential gene expression upon myotube differ-
entiation, it would be interesting to study in the futurewhether the
inhibitor mix is sufficient to induce dedifferentiation in mature
myofibers formed in vivo or indeed whether other factors are
required to yield regenerative cells.
SIGNIFICANCE
Use of pharmacological inhibitors to modulate different
signaling pathways without gene overexpression is thera-
peutically relevant in coaxing differentiated cells to yield
regenerative cells. Our data highlight the combinatorial
use of tyrosine phosphatase and apoptosis inhibitors for
primary myotube dedifferentiation to yield myogenic prolif-
erating cells, which aided in muscle regeneration both
in vitro and in vivo in SCID mice. The myotube labeling tech-
nique developed for this study served as a powerful tool to
clearly show the origin of reprogrammed cells and to sort
them away from reactivated reservemyoblasts. Importantly,
small molecule inhibitors induced changes in myotubes at
epigenetic level and facilitated them to enter proliferative
state inmitogen richmedium. All together, the labeling tech-Chemistry & Biology 18, 1153–116nique employed, along with the use of small molecule
inhibitors, advanced the ongoing research in regenerative
medicine and would enable unique clinical strategies for
enhancing tissue regeneration.
EXPERIMENTAL PROCEDURES
Animal Strains
B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetOPou5f1)Jae/J strain (stock
number: 006911), B6.129X1-Gt(ROSA)26Sor tm1(EYFP)Cos/J strain (stock
number: 006148), NOD.CB17-Prkdcscid/J (stock number: 001303), and
C57BL6/J (2–3 months old) mice were obtained from pathogen-free breeding
colonies at The Jackson Laboratories. Animals were housed at the Northwest
Animal Facility, University of California, Berkeley, and procedures were per-
formed in accordance to administrative panel on the Office of Laboratory
Animal Care, UC Berkeley.
Reagents, Antibodies, Western Blotting, and Immunofluorescence
BpV(phen) (Alexis Biochemicals), doxycycline (Sigma), and apoptosis inhibitor
(Q-VD-OPh, Non O methylated Cat No. 551476, Calbiochem), BrdU (Sigma),
ECM (Sigma), Hoechst 33342 (Sigma), DNase1 (Sigma), propidium iodide
(molecular probes), Rnase A (Fermentas), and mouse bFGF (R&D) were
purchased. Antibodies to BrdU (ab6326), GFP (ab6556 and ab13970), Ki67
(abcam ab155800), and Oct4 (ab18976) were from Abcam. Antibodies against
Actin (rabbit polyclonal) were from Sigma, Pax7 was from DSHB (Develop-
mental Studies Hybridoma Bank), eMyHC was from DSHB and Upstate, and
mouse monoclonal antibodies against myogenin, MyoD, and p21 were
from Santa Cruz Biotechnology. For Western blotting, the cells were lysed in
RIPA buffer (50 mM Tris-Cl [pH7.6], 150 mM NaCl, 0.1% SDS, 1% NP-40,
0.25% sodium deoxycholate, 1 mM sodium orthovanadate, 1 mM NaF,
1 mM PMSF, 1 mM EDTA, and 13 Protease inhibitor, Sigma), and protein
concentration was determined by Bradford Assay. Thirty micrograms
of protein was run on precast 4%–20%Gels (BioRad) and thenwas transferred
to nitrocellulose membrane for 2 hr, and protein expression was detected
by the BioRad Gel Doc/Chemi Doc imaging system and Quantity One
Software. For immunofluorescence, cells were fixed with 4% PFA for 15 min
at room temperature, followed by permeabilization with 0.25% Triton
X-100 for 12 min, and were blocked for 1 hr in blocking buffer (1% BGS
plus 0.1% Na-Azide in 13 PBS) followed by primary antibody incubation in
blocking buffer for 2 hr or overnight and secondary antibody incubation
for 1 hr in blocking buffer with Alexa fluorophore-conjugated species-
specific secondary antibody (Invitrogen). For BrdU labeling, cells were pulsed
with 10 mM BrdU for either 2 or 24 hr, fixed with 4% PFA for 15 min, and
permeabilized with 0.25% Triton X-100 for 12 min, followed by DNase1 treat-
ment (0.2 units/mL) for 30 min at room temperature. For all immunofluores-
cence assays, cells were mounted with mounting media containing DAPI
(Prolong Gold Antifade, Invitrogen) to visualize nuclei in all immunostaining
experiments.
Primary Myoblast Isolation
Primary myoblasts were obtained by isolation of satellite cells from thesemice,
as described previously (Conboy and Conboy, 2010). TA and gastrocnemius
muscle of the different transgenic mice were injected with a total of 5 mg of car-
diotoxin (Sigma) dissolved in 13 PBS, and muscle was dissected out after
3 days of injury, as described elsewhere (Conboy and Conboy, 2010). In brief,
muscle underwent enzymatic digestion at 37C in DMEM (Cellgro) plus 1%
penicillin/streptomycin plus 250 units/ml of Collagenase Type II (Sigma) solu-
tion for 1.5 hr on a rocker with slight agitation. Bulk myofibers were purified by
repeated rounds of trituration, sedimentation, and washing to remove intersti-
tial cells, tendons, and so froth. Satellite cells were purified from these bulk
myofibers by incubation in 0.5 units/ml dispase at 37C for 0.5 hr, followed
by sedimentation, washing, and fine mesh straining. The satellite cells were
then cultured on plates coated with 1:500 ECM (Sigma) in myoblast growth
medium containing Ham’s F-10 nutrient mixture (GIBCO) plus 20% bovine
growth serum (BGS; Hyclone), 9 ng/ml bFGF (R&D), and 1% penicillin/strepto-
mycin. Later, proliferating fusion-competent myoblasts were preplated to
remove fibroblasts from culture.6, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1163
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Myotube Reprogramming by Small Molecule InhibitorsAdenovirus Infection and Primary Myotube Labeling
Wild-typeMBor Tet-Oct4MB obtainedwere infectedwith Ad-CMV-Cre or Ad-
RFP control virus (Vector BioLabs) for 4–6 hr, washed off, and cultured in GM
for 24 hr. Ad-Cre MB were then lifted off the plates, counted, and cocultured
with Lox-YFP myoblasts in differentiation-inducing medium DMEM (Cellgro)
plus 2% horse serum (Sigma) and 1% penicillin/streptomycin (BD Falcon) on
12-well ECM-coated plates. The 96-hr-old myotubes were visualized for
YFP expression, treated with different experimental conditions, and photo-
graphed every day using a Zeiss epifluorescence microscope Axio Observer
A.1 fitted with a Zeiss EYFP filter (BP 500/20 FT515 BP 535/30) at 103 and
203 objective.
Dedifferentiation Assay
WTmyoblasts or Tet-Oct4 (33 105) myoblasts, upon 4–6 hr infection with 300
MOI of Ad-Cre virus, were washed with growth medium twice to get rid of any
residual virus and were incubated for another 24 hr in growth medium at 37C
in 5% CO2 incubator. These myoblasts were then lifted off the plates by the
addition of 13 PBS, counted (3 3 104 cells/well), and cocultured with 7 3
104 Lox-YFPmyoblasts (obtained fromB6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/
J mice strain) per well in differentiation-inducing medium DMEM (Cellgro) plus
2% horse serum and 1% penicillin/streptomycin on 12-well plates (BD Falcon)
coated with ECM (1:500). Later, 96-hr-old YFP+myotube cultures were treated
with BpV (phen) (10 mM) along with apoptosis/caspase inhibitor (Q-VD-OPh)
(10 mM) daily for 2 days with and without doxycycline (2 mg/ml) in differentiation
medium. The inhibitors were then withdrawn, and cells were switched to
growth medium containing bFGF (9 ng/ml). The treated cells were fed fresh
growthmedium and bFGF every day over a period of time, and themorphology
of YFP-expressing myotubes was routinely visualized by epifluorescence
microscope using a YFP filter and were photographed using 103 and 203
objectives. For live Hoechst staining, 4 mM of Hoechst was added every day
to YFP-labeled myotube cultures, incubated for 10 min at 37C in 5% CO2
incubator, washed off to remove unlabeled Hoechst, and photographed.
Calculation of Myotube Reprogramming Efficiency
The labeled YFP+ myotubes per well in 4-day-old Cre-Lox myotube cultures
were determined to be 2600. After inhibitor treatment, 350 YFP+ mononu-
cleated cells were found in culture. Hence, reprogramming efficiency was
calculated as the percentage of YFP+ mononucleated cells out of the total
number of labeled YFP+ myotubes, which was determined to be 13.46%.
Another method was based on the determination of Lox YFP myonuclei in
labeled myotubes. Because an average number of myonuclei present in
each YFP+ myotube is 4 and for myotube labeling, Cre and Lox YFP
myoblasts were cultured in a ratio of 1:2, hence Lox YFP myonuclei were esti-
mated to be 6940 [(2600 3 4) 3 2 / 3]. Therefore, reprogramming efficiency
calculated was the percentage of YFP+ mononucleated cells out of an esti-
mated total number of Lox YFP myonuclei in YFP+ myotubes and was deter-
mined to be 5.04% [(350 / 6940) 3 100] (see Figure S2D).
Cell Transplantation
Reprogrammed YFP+ mononucleated cells (1 3 106) expanded in GM in
culture were resuspended in medium containing Ham’s F-10 with 2% BGS
and were injected in 24-hr cardiotoxin preinjured TA muscles of NOD-SCID
mice (4 weeks old) obtained from Jackson Laboratories. Control injections
were performed with medium alone or with Lox YFP myoblasts resuspended
in medium. After 2–3 weeks of cell injections, TA muscles were dissected
out and fixed in 4% paraformaldehyde (PFA) for a minimum of 2 hr and subse-
quently were washed three times with 13 PBS for total of 45 min. The muscles
were then sequentially transferred to 2%, 5%, and 10% sucrose in PBS with
slight agitation at room temperature for 30 min to 1 hr. Finally, muscles were
left overnight in 20% sucrose at 4C and were frozen in liquid nitrogen-cooled
iso-pentane in OCT embedding medium. Muscle sections (10 mm) were cut
and mounted on superfrost slides; 300 mm serially spaced muscle sections
from whole block were postfixed with 4% PFA for 10 min, permeabilized for
10 min with 0.25% Triton X-100, and blocked in goat serum. Primary anti-
bodies against YFP (chicken polyclonal GFP, Abcam) and laminin (rat laminin
from Sigma) were added overnight, followed by 1 hr of incubation in the
respective fluorochrome-conjugated secondary antibodies (goat anti-chicken
488 and goat anti-rat 546) from Molecular probes.1164 Chemistry & Biology 18, 1153–1166, September 23, 2011 ª201RNA Isolation and qRT-PCR
RNA isolation was performed with an RNAeasy Kit (QIAGEN) according to the
manufacturer’s recommendations. For real-time qPCR, transcribed cDNAwas
diluted 1:5 for every sample, and 1 ml of this diluted cDNA was used for a 25-ml
PCR containing 80 nM forward and reverse primers, and 12.5 ml of 23 iQ Syber
Green mix (Bio-Rad) was run on an iQ5 cycler (Bio-Rad); data were analyzed
by iQ5 optical system software. The values were normalized against internal
control GAPDH and were plotted using the DDCt method. The primers against
specific genes for qRT-PCR are as follows: GAPDH-F, 50-GGGAAGCCCATCA
CCATCT-30 and GAPDH-R, 50-GCCTCACCCCATTTGATGTT-30; Myogenin-F,
50-GACCCTACAGACGCCCACAA and Myogenin-R, 50-CCGTGATGCTGTCC
ACGAT-30; MyoD-F, 50-CGGCTCTCTCTGCTCCTTTG-30 and MyoD-R, 50-GA
GTCGAAACACGGGTCATCA-30; Pax7-F, 50-CCCTCAGTGAGTTCGATTAGC-
30 and Pax7-R, 50-CCTTCCTCGTCGTCCTCTTTC-30; p21-F, 50GAACATCT
CAGGGCCGAAAA-30 and p21-R, 50-TGCGCTTGGAGTGATAGAAATC-30;
eMyHC-F, 50-AGAGGACGTGTATGCCATGA-30 and eMyHC-R, 50-TGGCCA
TGTCCTCAATCTTGT-30; Cre-recombinase-F, 50-GCCGGGTCAGAAAAAAT
GG and Cre recombinase-R, 50-AGGGCGCGAGTTGATAGCT-30; eYFP F,
50-GCACGACTTCTTCAAGTCCGCCATGCC-30 and eYFP R, 50-GCGGATCTT
GAAGTTCACCTTGATGCC-30. Primers for p15 and p16 have been described
elsewhere (Li et al., 2009). For SA biosciences/QIAGEN PCR arrays, 0.5 mg
RNA was reverse transcribed using SA biosciences RT kit, and PCR
arrays were performed according to the manufacturer’s instructions. The
Web-based PCR array data analysis tool of SA biosciences was utilized for
data analysis.
Flow Cytometry
De-differentiated YFP+ mononucleated cells were lifted off the plates by the
addition of PBS, resuspended in PBS plus 5% BSA, filtered through a
40-mM filter (BD Falcon) to remove any aggregates, and placed on ice. Cell
sorting was performed on a Cytopeia Influx sorter with gating on YFP+ popu-
lation set by a comparison with a negative control sample of Lox-YFP
myoblasts. The sorted cells were replated on ECM-coated tissue culture
dishes containing myoblast growth medium with 9 ng/ml bFGF and were
assessed for different markers. For cell-cycle analysis, dedifferentiated cells
were expanded in culture, pelleted down, and fixed in ice-cold 70% ethanol
overnight at 20C. The next day, cells were pelleted down at 1400 rpm for
5 min at 4C, and ethanol was removed. Cells were washed once with ice-
cold 13 DPBS and were resuspended in DNA staining solution (RNase,
0.1 mg/ml; propidium iodide, 2 mg/ml; and 0.05% Triton X-100 in 13 DPBS)
for 30 min at room temperature. The cells were pelleted down, washed once
with ice-cold DPBS, and resuspended in DPBS plus 3% BSA for FACS
analysis.
Statistical Analysis
p values were determined using student’s t test (2 samples equal variance,
2 tailed).
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